{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:53:39Z","timestamp":1761170019189,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":2519,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/gim.2014.79","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T11:19:31Z","timestamp":1404991171000},"page":"21-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?"],"prefix":"10.1016","volume":"17","author":[{"given":"Antonio","family":"Pisani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Pisani","key":"10.1038\/gim.2014.79_bb0010"},{"author":"Pisani","key":"10.1038\/gim.2014.79_bb0015"},{"key":"10.1038\/gim.2014.79_bb0020","unstructured":"Assessment Report on the Shortage of Fabrazyme. Overview of Shortage Period: Spontaneous Reports From June 2009 Through 15 September 2010 and Registry Data From June 2009 Through 05 August 2010. http:\/\/www.ema.eiropa.eu\/docs\/en_GB\/document_library\/Other\/2010\/11\/WC500099241.pdf Accessed 5 May 2014."},{"author":"Smid","key":"10.1038\/gim.2014.79_bb0025"},{"author":"Tsuboi","key":"10.1038\/gim.2014.79_bb0030"},{"author":"Pisani","key":"10.1038\/gim.2014.79_bb0035"},{"author":"Weidemann","key":"10.1038\/gim.2014.79_bb0040"},{"author":"Warnock","key":"10.1038\/gim.2014.79_bb0045"},{"author":"Tsuboi","key":"10.1038\/gim.2014.79_bb0050"},{"key":"10.1038\/gim.2014.79_bb0055","doi-asserted-by":"crossref","unstructured":"Tsuboi K, Yamamoto H, Somura F, Goto H. Successful management of enzyme replacement therapy in related Fabry disease patients with severe adverse events by switching from agalsidase beta (Fabrazyme\u00ae) to agalsidase alfa (Replagal \u00ae). JIMD Rep 2014; PMID: 24718841, e-pub ahead of print 10 April 2014.","DOI":"10.1007\/8904_2014_304"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gim201479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201479","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021049352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021049352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:45:19Z","timestamp":1761097519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360021049352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1098360021049352"],"URL":"https:\/\/doi.org\/10.1038\/gim.2014.79","relation":{},"ISSN":["1098-3600"],"issn-type":[{"type":"print","value":"1098-3600"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/gim.2014.79","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics","name":"copyright","label":"Copyright"}]}}